Skip to main content
BIOA logo

BIOA · BioAge Labs, Inc. · Documents

Track BIOA — free
$5.22 -0.33 (-5.95%) At close · Nov 16 Play latest call Q1 2026 earnings call transcript
Market Cap
$239.90M
Shares
45.96M
Volume · Nov 16 689.11K Avg daily vol (3M) 733.08K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $9M 10-K filed Mar 24, 2026 Quarterly report FY2026 Q3 Revenue $298K down 85.5% 10-Q filed Nov 5, 2026 Latest results Third-quarter net loss widens to $33.5 million 8-K filed Nov 5, 2026 Earnings call Q1 2026 earnings call Held Apr 21, 2026
2026
Nov 16
Investor event
BGE102 readouts ahead as runway reaches 2029

BioAge plans BGE102 data by year-end, QL-DME data in the second half of next year, and an APJ IND filing by year-end, supported by a little over $350 million in cash through 2029.

6 source passages
Our lead program is BGE102. We're targeting data, you know, committed to data at the end of this year. Remind us when we should expect the QLDME readout. So we're guiding to data in the second half of next year. we're guiding to filing our IND for the first APGA agonist program by the end of this year So we recently reported we have about a little over $350 million in cash. So that gets us, you know, essentially through 2029. Open the document at this passage
Nov 10
Investor event
BGE102 readouts and APJ filing anchor near-term pipeline catalysts

BioAge expects two BGE102 readouts later this year and in the second half of next year, plans an APJ IND filing by end of this year, and reported cash just north of 350 million with runway through 29.

4 source passages
Really pleased to be joined by BioAge. But broadly right now, our lead product is BGE102. This is a potential best-in-class brain penetrant NLRP3 inhibitor currently in two Phase II clinical trials with data coming later this year, as well as in the second half of next year. But we're also really excited to be back in the clinic again soon with APJ, so we're on track to file IND by end of this year, and that's when we'll give our sort of clinical timing as well for this really exciting target that's relevant to obesity and muscle. Yeah, at our last update, we were just north of 350 million, which gives us runway through 29 with all the programs we've discussed, as well as with, you know, another indication for NLRP3. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
BGE-102 advances in two Phase 2 trials

BioAge dosed first participants in QUELL-CV and QUELL-DME Phase 2 trials in June 2026 and September 2026. At September 30, 2026, it held $352.3 million in cash, cash equivalents, and marketable securities and expects funding through 2029.

Revenue $298K ▼ 85.5% Net loss $33.5M Diluted EPS -$0.73
Read from the MD&A section
5 source passages
In June 2026, we dosed the first participant in QUELL-CV, a randomized, double-blind, placebo-controlled, Phase 2 dose-ranging proof-of-concept trial evaluating BGE-102, measuring inflammatory and cardiometabolic biomarkers. In September 2026, we dosed the first participant in QUELL-DME, a randomized, controlled, three-arm Phase 2 trial evaluating once-daily oral BGE-102 in approximately 180 adults with DME, both as monotherapy and as an add-on to standard-of-care anti-VEGF intravitreal therapy. As of September 30, 2026, we had $352.3 million in cash, cash equivalents, and marketable securities. Based on our current operating plan, we estimate that our existing cash, cash equivalents, and marketable securities as of the filing date of this Quarterly Report will be sufficient to fund our operations and capital expenses through 2029. In October 2026, our AI-driven drug discovery collaboration with Deep Origin reached its first milestone, with hits identified computationally against a BioAge target validated in our laboratory. Open the document at this passage
Nov 5
Current report 8-K
Third-quarter net loss widens to $33.5 million

BioAge reported a net loss of $33.5 million for the quarter ended September 30, 2026 and approximately $352.3 million in cash, cash equivalents, and marketable securities. QUELL-CV topline data are anticipated in the fourth quarter of 2026, with funding projected through 2029.

Financial results
5 source passages
Net loss was $33.5 million for the quarter ended September 30, 2026, or $0.73 per weighted-average common share outstanding, basic and diluted, compared to a net loss of $20.2 million, or $0.56 per weighted-average common share outstanding, basic and diluted, for the same period in 2025. As of September 30, 2026, BioAge had approximately $352.3 million in cash, cash equivalents, and marketable securities. The trial is designed to characterize the dose-response relationship for BGE-102 and to support dose selection for further development, with topline data anticipated in the fourth quarter of 2026. Based on the Company’s current operating plan, BioAge estimates that existing cash, cash equivalents, and marketable securities will be sufficient to fund operations and capital expenses through 2029. QUELL-CV, a randomized, double-blind, placebo-controlled Phase 2 dose-ranging trial evaluating three once-daily oral doses of BGE-102 (30 mg, 60 mg, and 90 mg) against placebo in adults with obesity and elevated baseline inflammation, has completed enrollment of approximately 160 participants. Open the document at this passage
Oct 2
Current report 8-K
Other events

BioAge Labs, Inc. dosed the first participant in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102 in adults with diabetic macular edema. Topline results are expected in the second half of 2027.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $2.45M ▲ 1.6% Net loss $26.1M Diluted EPS -$0.58
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $2.77M ▲ 91.0% Net loss $22.25M Diluted EPS -$0.52
Apr 21
Proxy statement DEF 14A Meeting Jun 10, 2026
Proxy statement AI summary on its way
Mar 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $9M Net loss $80.61M Diluted EPS -$2.24
2025
2024
Showing 1–48 of 48 documents
Key facts CIK 1709941 CUSIP 09077V100 13F (30d) 129 filings 125 filers Visit website Investor relations